roxadustat

This page shows the latest roxadustat news and features for those working in and with pharma, biotech and healthcare.

GSK files anaemia drug daprodustat in Japan, its first market

Another oral HIF-PHI drug – AstraZeneca and FibroGen’s roxadustat– has already been approved in China for CKD anaemia.Additional competition could come from Akebia, which has a drug in the ... Astellas Pharma meanwhile has rights to roxadustat in

Latest news

AZ preps new roxadustat filings, though data foxes investors

Comes with increased blood pressure warning label. AstraZeneca and FibroGen say they are preparing a US filing of roxadustat for anaemia in chronic kidney disease after reporting cardiovascular outcomes data from ... There is a significant unmet medical
First-line ovarian approval cements AZ’s Lynparza lead

And in another positive development, AZ also announced today that two additional phase 3 trials of its just-approved drug for anaemia in chronic kidney disease patients – roxadustat – backed the efficacy
China first market to approve AZ’s kidney drug roxadustat

Roxadustat was compared to treatment with epoetin alfa over 26 weeks, matching the ESA’s efficacy in achieving a significant increase in haemoglobin levels. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while
AZ, FibroGen's anaemia drug on course for first filing this year

Roxadustat works by turning on the body's machinery for producing red blood cells that is usually stimulated by reduced oxygen levels in the blood. ... In addition, use of roxadustat is free of the burden of cold-chain storage and maintaining sterility,
GSK starts late-stage trials of daprodustat

administration.". GSK is in a race to market with other HIF-PHI developers, including FibroGen, which has a candidate called roxadustat (FG-4592) in late-stage trials in China for anaemia ... FibroGen said recently it is on track to file a marketing

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
China: AstraZeneca’s new engine for growth and innovation

Roxadustat is under accelerated review and, if approved, would also be the first locally- developed medicine to hit the Chinese market even before Europe and the US,” says Mallon. ... Finally, a data readout for roxadustat is expected by the end of 2018